U.S. & Europe Cartilage Regeneration Market - Industry Trends and Forecast to 2031

Description

List of Tables

The U.S. & EU cartilage regeneration market is expected to reach USD 1,859,291.40 thousand by 2031 from USD 669,950.40 thousand in 2023, growing at a CAGR of 15.7% during the forecast period of 2024-2031.

Market Segmentation

U.S. & EU Cartilage Regeneration Market, By Type (Hyaline Cartilage, Fibro Cartilage, and Elastic Cartilage), Treatment Modality (Cell-Based and Non-Cell Based), Treatment Type (Intrinsic Repair Stimulus and Palliative), Application Site (Knee, Hip, Ankle, Spine, and Others), Surgical Procedure (Osteochondral Transplantation, Autologous Chondrocyte Implantation, Matrix Autologous Cartilage Implantation (MACI), Chondroplasty and Microfracture, Osteotomy, Arthroscopy, Abrasion Arthroplasty, Juvenile Allograft Fragments, and Others), End User (Hospitals and Clinics, Academic and Research Institutes, Ambulatory Surgical Centers, Orthocenters, and Others), Country ( U.S., Germany, U.K, France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Turkey, Sweden, Belgium, Denmark, Finland, Norway, and rest of Europe) - Industry Trends and Forecast to 2031.

Overview of the U.S. & EU Cartilage Regeneration Market Dynamics

Drivers
Rising prevalence of osteoarthritis
Rising investments in research and development activities
Restraint
Poor reimbursement scenario
Opportunity
lack of trained and experienced professionals

Market Players

Some of the major companies operating in the U.S. & Europe cartilage regeneration market are:

Zimmer Biomet (U.S.)
Vericel Corporation. (U.S.)
Arthrex, Inc. (U.S.)
CONMED Corporation. (U.S.)
RTI Surgical (U.S.)
Smith+Nephew. (U.K.)
Anika Therapeutics, Inc. (U.S.)
Geistlich Pharma AG (Switzerland)
AlloSource (U.S.)
TETEC AG (Subsidiary of B. Braun SE) (Germany)
meidrix biomedicals GmbH. (Germany)
Bioinova, A.S. (Czech Republic)
Lamina Therapeutics (France)
CO.DON (Germany)
Novartis AG (Switzerland)
Cartilage Inc. (U.S.)
Histogen Inc. (U.S.)

1 INTRODUCTION 30

1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF THE U.S. & EU CARTILAGE REGENERATION MARKET 30
1.4 CURRENCY AND PRICING 32
1.5 LIMITATIONS 32
1.6 MARKETS COVERED 32

2 MARKET SEGMENTATION 35

2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 36
2.4 DBMR TRIPOD DATA VALIDATION MODEL 37
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 40
2.6 MULTIVARIATE MODELLING 41
2.7 TYPE SEGMENT LIFELINE CURVE 41
2.8 MARKET END USER COVERAGE GRID 42
2.9 DBMR MARKET POSITION GRID 43
2.10 VENDOR SHARE ANALYSIS 44
2.11 SECONDARY SOURCES 45
2.12 ASSUMPTIONS 45

3 EXECUTIVE SUMMARY 46

4 PREMIUM INSIGHTS 49

4.1 PSETEL ANALYSIS 50
4.2 PORTER'S FIVE FORCES 51

5 NUMBER OF PROCEDURES PERFORMED PER YEAR: BY COUNTRY 52

6 REGULATIONS 59

6.1 EUROPE CARTILAGE REGENERATION MARKET: REGULATIONS 59
- 6.1.1 CONFORMITY 59
- 6.1.2 CLINICAL INVESTIGATION 60
6.2 U.S. CARTLAGE REPAIRING MARKET: REGULATIONS 61
- 6.2.1 FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH (CDRH) 61
- 6.2.2 FDA CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) 61
- 6.2.3 CLINICAL TRIALS OVERSIGHT 61
- 6.2.4 POST-MARKET SURVEILLANCE 61

7 MARKET OVERVIEW 63

7.1 DRIVERS 65
- 7.1.1 RISING PREVALENCE OF OSTEOARTHRITIS 65
- 7.1.2 RISING INVESTMENTS IN RESEARCH AND DEVELOPMENT ACTIVITIES 65
- 7.1.3 RISING HEALTHCARE EXPENDITURE TO PROMOTE CARTILAGE REGENERATION TREATMENT 66
- 7.1.4 INCREASING NUMBER OF JOINT INJURIES 66
7.2 RESTRAINTS 67
- 7.2.1 POOR REIMBURSEMENT SCENARIO FOR CARTILAGE REGENERATION 67
- 7.2.2 STRINGENT REGULATIONS FOR THE APPROVAL OF CARTILAGE REGENERATION PRODUCTS 67
7.3 OPPORTUNITIES 68
- 7.3.1 INCREASE DEMAND FOR MINIMALLY INVASIVE PROCEDURES 68
- 7.3.2 RISING TECHNOLOGICAL ADVANCEMENTS IN THE CARTILAGE REGENERATION PROCESS. 69
- 7.3.3 RISING AWARENESS OF MEDICAL TREATMENT IN EUROPE 70
7.4 CHALLENGES 70
- 7.4.1 LACK OF SKILLED PROFESSIONALS IN HEALTHCARE MARKET 70
- 7.4.2 HIGH COST OF ORTHOPEDIC IMPLANTS AND SURGERIES 71

8 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TYPE 72

8.1 OVERVIEW 73
8.2 HYALINE CARTILAGE 76
8.3 FIBRO CARTILAGE 76
- 8.3.1 INTRA-ARTICULAR FIBROCARTILAGE 76
- 8.3.2 STRATIFORM FIBROCARTILAGE 76
- 8.3.3 CIRCUMFERENTIAL FIBROCARTILAGE 76
- 8.3.4 CONNECTING FIBROCARTILAGE 77
8.4 ELASTIC CARTILAGE 77

9 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY 78

9.1 OVERVIEW 79
9.2 CELL-BASED 82
- 9.2.1 CHONDROCYTE TRANSPLANTATION 82
  - 9.2.1.1 AUTOLOGOUS CHONDROCYTE IMPLANTATION (ACI) 82
  - 9.2.1.2 MATRIX-INDUCED AUTOLOGOUS CHONDROCYTE IMPLANTATION (MACI) 83
- 9.2.2 STEM CELLS 83
  - 9.2.2.1 MESENCHYMAL STEM CELLS (MSC'S) 83
  - 9.2.2.2 UMBILICAL CORD-DERIVED STEM CELL THERAPY 83
  - 9.2.2.3 EMBRYONIC STEM CELL THERAPY 83
  - 9.2.2.4 OTHERS 83
- 9.2.3 GROWTH FACTOR 84
  - 9.2.3.1 PLATELET-RICH PLASMA (PRP) 84
  - 9.2.3.2 AUTOLOGOUS CONDITIONED SERUM (ACS) 84
  - 9.2.3.3 BONE MORPHOGENETIC PROTEIN (BMP) PRODUCTS 84
  - 9.2.3.4 FIBROBLAST GROWTH FACTOR (FGF) PRODUCTS 84
  - 9.2.3.5 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) PRODUCTS 84
  - 9.2.3.6 OTHERS 85
- 9.2.4 OTHERS 85
9.3 NON - CELL BASED 85
- 9.3.1 SCAFFOLDS 85
  - 9.3.1.1 NATURAL 86
    - 9.3.1.1.1 HYALURONIC ACID (HA) PRODUCTS 86
    - 9.3.1.1.2 COLLAGEN-BASED SCAFFOLDS 86
    - 9.3.1.1.3 CHITOSAN SCAFFOLDS 86
    - 9.3.1.1.4 DECELLULARIZED EXTRACELLULAR MATRIX 86
    - 9.3.1.1.5 OTHERS 86
  - 9.3.1.2 SYNTHETIC 87
    - 9.3.1.2.1 POLY (LACTIC-CO-GLYCOLIC ACID) (PLGA) SCAFFOLDS 87
    - 9.3.1.2.2 POLYETHYLENE GLYCOL (PEG) HYDROGELS: 87
    - 9.3.1.2.3 OTHERS 87
- 9.3.2 CELL-FREE COMPOSITES 88
  - 9.3.2.1 ARTIFICIAL CARTILAGE IMPLANT 88
  - 9.3.2.2 OTHERS 88

10 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE 89

10.1 OVERVIEW 90
10.2 INTRINSIC REPAIR STIMULUS 93
10.3 PALLIATIVE 93
- 10.3.1 DEBRIDEMENT & LAVAGE 93
- 10.3.2 VISCOSUPPLEMENTATION 93

11 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE 94

11.1 OVERVIEW 95
11.2 KNEE 98
- 11.2.1 OSTEOCHONDRIAL GRAFTS TRANSPLANTATION 98
- 11.2.2 AUTOLOGOUS CHONDROCYTE 98
- 11.2.3 ARTHROSCOPIC CHONDROPLASTY 98
- 11.2.4 MICROFRACTURE 98
- 11.2.5 CELL-BASED CARTILAGE RESURFACING 99
- 11.2.6 OTHERS 99
11.3 HIP 99
11.4 ANKLE 99
11.5 SPINE 99
11.6 OTHERS 99

12 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURES 100

12.1 OVERVIEW 101
12.2 OSTEOCHONDRIAL TRANSPLANTATION 104
- 12.2.1 OSTEOCHONDRIAL AUTOGRAFT TRANSPLANTATION 104
- 12.2.2 OSTEOCHONDRIAL ALLOGRAFT TRANSPLANTATION 104
12.3 AUTOLOGOUS CHONDROCYTE IMPLANTATION 104
12.4 MATRIX AUTOLOGOUS CARTILAGE IMPLANTATION (MACI) 104
12.5 CHONDROPLASTY AND MICROFRACTURE 104
12.6 OSTEOTOMY 105
12.7 ARTHROSCOPY 105
12.8 ABRASION ARTHROPLASTY 105
12.9 JUVENILE ALLOGRAFT FRAGMENTS 105
12.10 OTHERS 105

13 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY END USER 106

13.1 OVERVIEW 107
13.2 HOSPITALS AND CLINICS 110
- 13.2.1 PRIVATE 110
- 13.2.2 PUBLIC 110
13.3 ACADEMIC AND RESEARCH INSTITUTES 110
13.4 AMBULATORY SURGICAL CENTERS 110
13.5 ORTHOCENTERS 111
13.6 OTHERS 111

14 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY REGION 112

14.1 U.S. 112
14.2 EUROPE 119
- 14.2.1 GERMANY 129
- 14.2.2 U.K. 136
- 14.2.3 FRANCE 143
- 14.2.4 ITALY 150
- 14.2.5 SPAIN 157
- 14.2.6 RUSSIA 164
- 14.2.7 POLAND 171
- 14.2.8 SWITZERLAND 178
- 14.2.9 NETHERLANDS 185
- 14.2.10 TURKEY 192
- 14.2.11 SWEDEN 199
- 14.2.12 BELGIUM 206
- 14.2.13 DENMARK 213
- 14.2.14 FINLAND 220
- 14.2.15 NORWAY 227
- 14.2.16 REST OF EUROPE 234

15 U.S. CARTILAGE REGENERATION MARKET: COMPANY LANDSCAPE 235

15.1 COMPANY SHARE ANALYSIS: U.S. 235
15.2 COMPANY SHARE ANALYSIS: EUROPE 236

16 COMPANY PROFILE 237

16.1 ZIMMER BIOMET 237
- 16.1.1 COMPANY SNAPSHOT 237
- 16.1.2 REVENUE ANALYSIS 237
- 16.1.3 PRODUCT PORTFOLIO 238
- 16.1.4 RECENT DEVELOPMENTS 238
16.2 VERICEL CORPORATION. 239
- 16.2.1 COMPANY SNAPSHOT 239
- 16.2.2 REVENUE ANALYSIS 239
- 16.2.3 PRODUCT PORTFOLIO 240
- 16.2.4 RECENT DEVELOPMENT 240
16.3 ARTHREX, INC. 241
- 16.3.1 COMPANY SNAPSHOT 241
- 16.3.2 PRODUCT PORTFOLIO 241
- 16.3.3 RECENT DEVELOPMENT 242
16.4 CONMED 243
- 16.4.1 COMPANY SNAPSHOT 243
- 16.4.2 REVENUE ANALYSIS 243
- 16.4.3 PRODUCT PORTFOLIO 244
- 16.4.4 RECENT DEVELOPMENT 244
16.5 RTI SURGICAL 245
- 16.5.1 COMPANY SNAPSHOT 245
- 16.5.2 PRODUCT PORTFOLIO 245
- 16.5.3 RECENT DEVELOPMENT 245
16.6 ALLOSOURCE 246
- 16.6.1 COMPANY SNAPSHOT 246
- 16.6.2 PRODUCT PORTFOLIO 246
- 16.6.3 RECENT DEVELOPMENT 246
16.7 ANIKA THERAPEUTICS, INC. 247
- 16.7.1 COMPANY SNAPSHOT 247
- 16.7.2 REVENUE ANALYSIS 247
- 16.7.3 1.4.4 PRODUCT PORTFOLIO 248
- 16.7.4 RECENT DEVELOPMENT 248
16.8 BIOINOVA, A.S. 249
- 16.8.1 COMPANY SNAPSHOT 249
- 16.8.2 PRODUCT PORTFOLIO 249
- 16.8.3 RECENT DEVELOPMENT 249
16.9 CARTILAGE INC. 250
- 16.9.1 COMPANY SNAPSHOT 250
- 16.9.2 PRODUCT PORTFOLIO 250
- 16.9.3 RECENT DEVELOPMENT 250
16.10 CO.DON 252
- 16.10.1 COMPANY SNAPSHOT 252
- 16.10.2 PRODUCT PORTFOLIO 252
- 16.10.3 RECENT DEVELOPMENT 252
16.11 GEISTLICH PHARMA AG 253
- 16.11.1 COMPANY SNAPSHOT 253
- 16.11.2 PRODUCT PORTFOLIO 253
- 16.11.3 RECENT DEVELOPMENT 253
16.12 HISTOGEN INC. 254
- 16.12.1 COMPANY SNAPSHOT 254
- 16.12.2 PRODUCT PORTFOLIO 254
- 16.12.3 RECENT DEVELOPMENT 255
16.13 LAMINA THERAPEUTICS 256
- 16.13.1 COMPANY SNAPSHOT 256
- 16.13.2 PRODUCT PORTFOLIO 256
- 16.13.3 RECENT DEVELOPMENT 256
16.14 MEIDRIX BIOMEDICALS GMBH 257
- 16.14.1 COMPANY SNAPSHOT 257
- 16.14.2 PRODUCT PORTFOLIO 257
- 16.14.3 RECENT DEVELOPMENT 257
16.15 NOVARTIS AG 258
- 16.15.1 COMPANY SNAPSHOT 258
- 16.15.2 PRODUCT PORTFOLIO 258
- 16.15.3 RECENT DEVELOPMENT 259
16.16 SMITH & NEPHEW 260
- 16.16.1 COMPANY SNAPSHOT 260
- 16.16.2 REVENUE ANALYSIS 260
- 16.16.3 PRODUCT PORTFOLIO 261
- 16.16.4 RECENT DEVELOPMENTS 261
16.17 TETEC AG 263
- 16.17.1 COMPANY SNAPSHOT 263
- 16.17.2 PRODUCT PORTFOLIO 263
- 16.17.3 RECENT DEVELOPMENT 263

17 QUESTIONNAIRE 264

18 RELATED REPORTS 268

LIST OF TABLES

TABLE 1 U.S. NUMBER OF PROCEDURES PER YEAR 52
TABLE 2 GERMANY NUMBER OF PROCEDURES PER YEAR 52
TABLE 3 U.K. NUMBER OF PROCEDURES PER YEAR 53
TABLE 4 FRANCE NUMBER OF PROCEDURES PER YEAR 53
TABLE 5 ITALY NUMBER OF PROCEDURES PER YEAR 54
TABLE 6 SPAIN NUMBER OF PROCEDURES PER YEAR 54
TABLE 7 RUSSIA NUMBER OF PROCEDURES PER YEAR 55
TABLE 8 POLAND NUMBER OF PROCEDURES PER YEAR 55
TABLE 9 SWITZERLAND NUMBER OF PROCEDURES PER YEAR 56
TABLE 10 NETHERLANDS NUMBER OF PROCEDURES PER YEAR 56
TABLE 11 TURKEY NUMBER OF PROCEDURES PER YEAR 56
TABLE 12 SWEDEN NUMBER OF PROCEDURES PER YEAR 57
TABLE 13 BELGIUM NUMBER OF PROCEDURES PER YEAR 57
TABLE 14 DENMARK NUMBER OF PROCEDURES PER YEAR 57
TABLE 15 FINLAND NUMBER OF PROCEDURES PER YEAR 58
TABLE 16 NORWAY NUMBER OF PROCEDURES PER YEAR 58
TABLE 17 COST OF PROCEDURES 71
TABLE 18 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 75
TABLE 19 U.S. & EUROPE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 76
TABLE 20 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 81
TABLE 21 U.S. & EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 82
TABLE 22 U.S. & EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 82
TABLE 23 U.S. & EUROPE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 83
TABLE 24 U.S. & EUROPE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 84
TABLE 25 U.S. & EUROPE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 85
TABLE 26 U.S. & EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 85
TABLE 27 U.S. & EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 86
TABLE 28 U.S. & EUROPE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 87
TABLE 29 U.S. & EUROPE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 88
TABLE 30 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 92
TABLE 31 U.S. & EUROPE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 93
TABLE 32 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 97
TABLE 33 U.S. & EUROPE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 98
TABLE 34 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 103
TABLE 35 U.S. & EUROPE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 104
TABLE 36 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 109
TABLE 37 U.S. & EUROPE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 110
TABLE 38 U.S. CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 112
TABLE 39 U.S. FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 112
TABLE 40 U.S. CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 112
TABLE 41 U.S. CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 113
TABLE 42 U.S. CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 113
TABLE 43 U.S. STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 113
TABLE 44 U.S. GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 114
TABLE 45 U.S. NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 114
TABLE 46 U.S. SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 114
TABLE 47 U.S. NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 115
TABLE 48 U.S. SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 115
TABLE 49 U.S. CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 115
TABLE 50 U.S. CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 116
TABLE 51 U.S. PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 116
TABLE 52 U.S. CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 116
TABLE 53 U.S. KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 117
TABLE 54 U.S. CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 117
TABLE 55 U.S. OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 118
TABLE 56 U.S. CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 118
TABLE 57 U.S. HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 118
TABLE 58 EUROPE CARTILAGE REGENERATION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 121
TABLE 59 EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 122
TABLE 60 EUROPE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 122
TABLE 61 EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 122
TABLE 62 EUROPE CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 123
TABLE 63 EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 123
TABLE 64 EUROPE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 123
TABLE 65 EUROPE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 124
TABLE 66 EUROPE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 124
TABLE 67 EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 124
TABLE 68 EUROPE NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 125
TABLE 69 EUROPE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 125
TABLE 70 EUROPE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 125
TABLE 71 EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 126
TABLE 72 EUROPE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 126
TABLE 73 EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 126
TABLE 74 EUROPE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 127
TABLE 75 EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 127
TABLE 76 EUROPE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 128
TABLE 77 EUROPE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 128
TABLE 78 EUROPE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 128
TABLE 79 GERMANY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 129
TABLE 80 GERMANY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 129
TABLE 81 GERMANY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 129
TABLE 82 GERMANY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 130
TABLE 83 GERMANY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 130
TABLE 84 GERMANY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 130
TABLE 85 GERMANY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 131
TABLE 86 GERMANY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 131
TABLE 87 GERMANY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 131
TABLE 88 GERMANY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 132
TABLE 89 GERMANY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 132
TABLE 90 GERMANY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 132
TABLE 91 GERMANY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 133
TABLE 92 GERMANY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 133
TABLE 93 GERMANY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 133
TABLE 94 GERMANY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 134
TABLE 95 GERMANY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 134
TABLE 96 GERMANY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 135
TABLE 97 GERMANY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 135
TABLE 98 GERMANY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 135
TABLE 99 U.K. CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 136
TABLE 100 U.K. FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 136
TABLE 101 U.K. CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 136
TABLE 102 U.K. CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 137
TABLE 103 U.K. CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 137
TABLE 104 U.K. STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 137
TABLE 105 U.K. GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 138
TABLE 106 U.K. NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 138
TABLE 107 U.K. SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 138
TABLE 108 U.K. NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 139
TABLE 109 U.K. SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 139
TABLE 110 U.K. CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 139
TABLE 111 U.K. CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 140
TABLE 112 U.K. PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 140
TABLE 113 U.K. CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 140
TABLE 114 U.K. KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 141
TABLE 115 U.K. CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 141
TABLE 116 U.K. OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 142
TABLE 117 U.K. CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 142
TABLE 118 U.K. HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 142
TABLE 119 FRANCE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 143
TABLE 120 FRANCE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 143
TABLE 121 FRANCE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 143
TABLE 122 FRANCE CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 144
TABLE 123 FRANCE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 144
TABLE 124 FRANCE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 144
TABLE 125 FRANCE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 145
TABLE 126 FRANCE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 145
TABLE 127 FRANCE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 145
TABLE 128 FRANCE NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 146
TABLE 129 FRANCE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 146
TABLE 130 FRANCE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 146
TABLE 131 FRANCE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 147
TABLE 132 FRANCE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 147
TABLE 133 FRANCE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 147
TABLE 134 FRANCE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 148
TABLE 135 FRANCE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 148
TABLE 136 FRANCE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 149
TABLE 137 FRANCE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 149
TABLE 138 FRANCE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 149
TABLE 139 ITALY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 150
TABLE 140 ITALY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 150
TABLE 141 ITALY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 150
TABLE 142 ITALY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 151
TABLE 143 ITALY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 151
TABLE 144 ITALY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 151
TABLE 145 ITALY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 152
TABLE 146 ITALY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 152
TABLE 147 ITALY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 152
TABLE 148 ITALY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 153
TABLE 149 ITALY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 153
TABLE 150 ITALY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 153
TABLE 151 ITALY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 154
TABLE 152 ITALY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 154
TABLE 153 ITALY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 154
TABLE 154 ITALY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 155
TABLE 155 ITALY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 155
TABLE 156 ITALY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 156
TABLE 157 ITALY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 156
TABLE 158 ITALY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 156
TABLE 159 SPAIN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 157
TABLE 160 SPAIN FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 157
TABLE 161 SPAIN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 157
TABLE 162 SPAIN CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 158
TABLE 163 SPAIN CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 158
TABLE 164 SPAIN STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 158
TABLE 165 SPAIN GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 159
TABLE 166 SPAIN NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 159
TABLE 167 SPAIN SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 159
TABLE 168 SPAIN NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 160
TABLE 169 SPAIN SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 160
TABLE 170 SPAIN CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 160
TABLE 171 SPAIN CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 161
TABLE 172 SPAIN PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 161
TABLE 173 SPAIN CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 161
TABLE 174 SPAIN KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 162
TABLE 175 SPAIN CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 162
TABLE 176 SPAIN OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 163
TABLE 177 SPAIN CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 163
TABLE 178 SPAIN HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 163
TABLE 179 RUSSIA CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 164
TABLE 180 RUSSIA FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 164
TABLE 181 RUSSIA CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 164
TABLE 182 RUSSIA CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 165
TABLE 183 RUSSIA CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 165
TABLE 184 RUSSIA STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 165
TABLE 185 RUSSIA GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 166
TABLE 186 RUSSIA NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 166
TABLE 187 RUSSIA SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 166
TABLE 188 RUSSIA NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 167
TABLE 189 RUSSIA SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 167
TABLE 190 RUSSIA CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 167
TABLE 191 RUSSIA CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 168
TABLE 192 RUSSIA PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 168
TABLE 193 RUSSIA CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 168
TABLE 194 RUSSIA KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 169
TABLE 195 RUSSIA CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 169
TABLE 196 RUSSIA OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 170
TABLE 197 RUSSIA CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 170
TABLE 198 RUSSIA HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 170
TABLE 199 POLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 171
TABLE 200 POLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 171
TABLE 201 POLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 171
TABLE 202 POLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 172
TABLE 203 POLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 172
TABLE 204 POLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 172
TABLE 205 POLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 173
TABLE 206 POLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 173
TABLE 207 POLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 173
TABLE 208 POLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 174
TABLE 209 POLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 174
TABLE 210 POLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 174
TABLE 211 POLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 175
TABLE 212 POLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 175
TABLE 213 POLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 175
TABLE 214 POLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 176
TABLE 215 POLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 176
TABLE 216 POLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 177
TABLE 217 POLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 177
TABLE 218 POLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 177
TABLE 219 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 178
TABLE 220 SWITZERLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 178
TABLE 221 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 178
TABLE 222 SWITZERLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 179
TABLE 223 SWITZERLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 179
TABLE 224 SWITZERLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 179
TABLE 225 SWITZERLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 180
TABLE 226 SWITZERLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 180
TABLE 227 SWITZERLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 180
TABLE 228 SWITZERLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 181
TABLE 229 SWITZERLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 181
TABLE 230 SWITZERLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 181
TABLE 231 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 182
TABLE 232 SWITZERLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 182
TABLE 233 SWITZERLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 182
TABLE 234 SWITZERLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 183
TABLE 235 SWITZERLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 183
TABLE 236 SWITZERLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 184
TABLE 237 SWITZERLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 184
TABLE 238 SWITZERLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 184
TABLE 239 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 185
TABLE 240 NETHERLANDS FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 185
TABLE 241 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 185
TABLE 242 NETHERLANDS CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 186
TABLE 243 NETHERLANDS CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 186
TABLE 244 NETHERLANDS STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 186
TABLE 245 NETHERLANDS GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 187
TABLE 246 NETHERLANDS NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 187
TABLE 247 NETHERLANDS SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 187

TABLE 248 NETHERLANDS NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 188
TABLE 249 NETHERLANDS SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 188
TABLE 250 NETHERLANDS CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 188
TABLE 251 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 189
TABLE 252 NETHERLANDS PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 189
TABLE 253 NETHERLANDS CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 189
TABLE 254 NETHERLANDS KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 190
TABLE 255 NETHERLANDS CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 190
TABLE 256 NETHERLANDS OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 191
TABLE 257 NETHERLANDS CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 191
TABLE 258 NETHERLANDS HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 191
TABLE 259 TURKEY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 192
TABLE 260 TURKEY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 192
TABLE 261 TURKEY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 192
TABLE 262 TURKEY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 193
TABLE 263 TURKEY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 193
TABLE 264 TURKEY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 193
TABLE 265 TURKEY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 194
TABLE 266 TURKEY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 194
TABLE 267 TURKEY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 194
TABLE 268 TURKEY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 195
TABLE 269 TURKEY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 195
TABLE 270 TURKEY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 195
TABLE 271 TURKEY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 196
TABLE 272 TURKEY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 196
TABLE 273 TURKEY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 196
TABLE 274 TURKEY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 197
TABLE 275 TURKEY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 197
TABLE 276 TURKEY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 198
TABLE 277 TURKEY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 198
TABLE 278 TURKEY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 198
TABLE 279 SWEDEN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 199
TABLE 280 SWEDEN FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 199
TABLE 281 SWEDEN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 199
TABLE 282 SWEDEN CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 200
TABLE 283 SWEDEN CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 200
TABLE 284 SWEDEN STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 200
TABLE 285 SWEDEN GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 201
TABLE 286 SWEDEN NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 201
TABLE 287 SWEDEN SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 201
TABLE 288 SWEDEN NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 202
TABLE 289 SWEDEN SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 202
TABLE 290 SWEDEN CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 202
TABLE 291 SWEDEN CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 203
TABLE 292 SWEDEN PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 203
TABLE 293 SWEDEN CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 203
TABLE 294 SWEDEN KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 204
TABLE 295 SWEDEN CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 204
TABLE 296 SWEDEN OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 205
TABLE 297 SWEDEN CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 205
TABLE 298 SWEDEN HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 205
TABLE 299 BELGIUM CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 206
TABLE 300 BELGIUM FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 206
TABLE 301 BELGIUM CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 206
TABLE 302 BELGIUM CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 207
TABLE 303 BELGIUM CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 207
TABLE 304 BELGIUM STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 207
TABLE 305 BELGIUM GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 208
TABLE 306 BELGIUM NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 208
TABLE 307 BELGIUM SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 208
TABLE 308 BELGIUM NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 209
TABLE 309 BELGIUM SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 209
TABLE 310 BELGIUM CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 209
TABLE 311 BELGIUM CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 210
TABLE 312 BELGIUM PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 210
TABLE 313 BELGIUM CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 210
TABLE 314 BELGIUM KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 211
TABLE 315 BELGIUM CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 211
TABLE 316 BELGIUM OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 212
TABLE 317 BELGIUM CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 212
TABLE 318 BELGIUM HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 212
TABLE 319 DENMARK CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 213
TABLE 320 DENMARK FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 213
TABLE 321 DENMARK CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 213
TABLE 322 DENMARK CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 214
TABLE 323 DENMARK CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 214
TABLE 324 DENMARK STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 214
TABLE 325 DENMARK GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 215
TABLE 326 DENMARK NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 215
TABLE 327 DENMARK SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 215
TABLE 328 DENMARK NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 216
TABLE 329 DENMARK SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 216
TABLE 330 DENMARK CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 216
TABLE 331 DENMARK CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 217
TABLE 332 DENMARK PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 217
TABLE 333 DENMARK CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 217
TABLE 334 DENMARK KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 218
TABLE 335 DENMARK CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 218
TABLE 336 DENMARK OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 219
TABLE 337 DENMARK CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 219
TABLE 338 DENMARK HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 219
TABLE 339 FINLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 220
TABLE 340 FINLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 220
TABLE 341 FINLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 220
TABLE 342 FINLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 221
TABLE 343 FINLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 221
TABLE 344 FINLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 221
TABLE 345 FINLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 222
TABLE 346 FINLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 222
TABLE 347 FINLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 222
TABLE 348 FINLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 223
TABLE 349 FINLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 223
TABLE 350 FINLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 223
TABLE 351 FINLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 224
TABLE 352 FINLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 224
TABLE 353 FINLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 224
TABLE 354 FINLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 225
TABLE 355 FINLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 225
TABLE 356 FINLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 226
TABLE 357 FINLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 226
TABLE 358 FINLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 226
TABLE 359 NORWAY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 227
TABLE 360 NORWAY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 227
TABLE 361 NORWAY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 227
TABLE 362 NORWAY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 228
TABLE 363 NORWAY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 228
TABLE 364 NORWAY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 228
TABLE 365 NORWAY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 229
TABLE 366 NORWAY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 229
TABLE 367 NORWAY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 229
TABLE 368 NORWAY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 230
TABLE 369 NORWAY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 230
TABLE 370 NORWAY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND) 230
TABLE 371 NORWAY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 230
TABLE 372 NORWAY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 231
TABLE 373 NORWAY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND) 231
TABLE 374 NORWAY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 231
TABLE 375 NORWAY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND) 232
TABLE 376 NORWAY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 232
TABLE 377 NORWAY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 233
TABLE 378 NORWAY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 233
TABLE 379 REST OF EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 234

LIST OF FIGURES

FIGURE 1 U.S. & EU CARTILAGE REGENERATION MARKET: SEGMENTATION 35
FIGURE 2 U.S. & EU CARTILAGE REGENERATION MARKET: DATA TRIANGULATION 37
FIGURE 3 U.S. & EU CARTILAGE REGENERATION MARKET: DROC ANALYSIS 38
FIGURE 4 U.S. & EU CARTILAGE REGENERATION MARKET: REGIONAL VS COUNTRYMARKET ANALYSIS 39
FIGURE 5 U.S. & EU CARTILAGE REGENERATION MARKET: COMPANY RESEARCH ANALYSIS 39
FIGURE 6 U.S. & EU CARTILAGE REGENERATION MARKET: INTERVIEW DEMOGRAPHICS 40
FIGURE 7 U.S. & EU CARTILAGE REGENERATION MARKET: MARKET END USER COVERAGE GRID 42
FIGURE 8 U.S. & EU CARTILAGE REGENERATION MARKET: DBMR MARKET POSITION GRID 43
FIGURE 9 U.S. & EU CARTILAGE REGENERATION MARKET: VENDOR SHARE ANALYSIS 44
FIGURE 10 U.S. & EU CARTILAGE REGENERATION MARKET: SEGMENTATION 48
FIGURE 11 RISING PREVALENCE OF OSTEOARTHRITIS AND RISING HEALTHCARE EXPENDITURE ARE DRIVING THE GROWTH OF THE U.S. & EU CARTILAGE REGENERATION MARKET FROM 2024 TO 2034 49
FIGURE 12 HYALINE CARTILAGE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. AND EU CARTILAGE REGENERATION MARKET IN 2024 TO 2031 49
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE U.S. & EU CARTILAGE REGENERATION MARKET 64
FIGURE 14 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, 2023 73
FIGURE 15 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, 2024-2031 (USD THOUSAND) 74
FIGURE 16 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, CAGR (2024-2031) 74
FIGURE 17 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, LIFELINE CURVE 75
FIGURE 18 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, 2022 79
FIGURE 19 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, 2024-2031 (USD THOUSAND) 80
FIGURE 20 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, CAGR (2024-2031) 80
FIGURE 21 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, LIFELINE CURVE 81
FIGURE 22 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, 2022 90
FIGURE 23 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND) 91
FIGURE 24 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, CAGR (2024-2031) 91
FIGURE 25 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, LIFELINE CURVE 92
FIGURE 26 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, 2023 95
FIGURE 27 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, 2024-2031 (USD THOUSAND) 96
FIGURE 28 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, CAGR (2024-2031) 96
FIGURE 29 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, LIFELINE CURVE 97
FIGURE 30 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE , 2023 101
FIGURE 31 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE , 2024-2031 (USD THOUSAND) 102
FIGURE 32 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE, CAGR (2024-2031) 102
FIGURE 33 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE, LIFELINE CURVE 103
FIGURE 34 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, 2023 107
FIGURE 35 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, 2024-2031 (USD THOUSAND) 108
FIGURE 36 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, CAGR (2024-2031) 108
FIGURE 37 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, LIFELINE CURVE 109
FIGURE 38 EUROPE CARTILAGE REGENERATION MARKET: SNAPSHOT (2023) 120
FIGURE 39 U.S. CARTILAGE REGENERATION MARKET: COMPANY SHARE 2023 (%) 235
FIGURE 40 EUROPE CARTILAGE REGENERATION MARKET: COMPANY SHARE 2023 (%) 236